Thal amyloid stages do not significantly impact the correlation between neuropathological change and cognition in the Alzheimer disease continuum

Journal of Neuropathology and Experimental Neurology

Volumn 75, Issue 6, 2016, Pages 516-526

  Serrano Pozo, Alberto ^a   Qian, Jing ^b   Muzikansky, Alona ^c   Monsell, Sarah E ^d   Montine, Thomas J ^e   Frosch, Matthew P ^c,g   Betensky, Rebecca A ^f,g   Hyman, Bradley T ^c,g  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g Massachusetts Alzheimer Disease Research Center   (United States)

Author keywords

ABC score; Alzheimer disease; Amyloid plaques; National Alzheimer's coordinating center; Neuritic plaques; Neurofibrillary tangles; Thal stages

Indexed keywords

AMYLOID;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; CLINICAL DEMENTIA RATING SUM OF BOXES; COGNITION; FEMALE; GENERAL PATHOLOGICAL PARAMETERS; HUMAN; LONGITUDINAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; SENILE PLAQUE; THAL AMYLOID STAGE; AMYLOID PLAQUE; AMYLOIDOSIS; CLINICAL TRIAL; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE EXACERBATION; MULTICENTER STUDY; PATHOLOGY; PSYCHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; COGNITION DISORDERS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID;

EID: 84983247444     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1093/jnen/nlw026     Document Type: Article

References (41)

1. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement J Alzheimers Assoc 2012;8:1-13
2. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012;123:1-11
3. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of alzheimer's disease. Neurobiol Aging 1997;18:S1-2
4. Thal DR, Rüb U, Orantes M, et al. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
6. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer diseaseassociated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389-404
7. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
8. Matthews FE, Brayne C, Lowe J, et al. Epidemiological pathology of dementia: Attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 2009;6:e1000180
9. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169-75
10. Serrano-Pozo A, Qiang J, Monsell SE, et al. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol 2013;72:1182-92
11. Beekly DL, Ramos EM, Lee WW, et al. The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. Alzheimer Dis Assoc Disord 2007;21:249-58
12. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-6
13. Weintraub S, Salmon D, Mercaldo N, et al. The Alzheimer's Disease Centers' Uniform Data Set (UDS): The neuropsychologic test battery. Alzheimer Dis Assoc Disord 2009;23:91-101
14. Dolan H, Crain B, Troncoso J, et al. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol 2010;68:231-40
15. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197-204
16. Sonnen JA, Larson EB, Crane PK, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 2007;62:406-13
17. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-4
18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98
19. Agresti A, Agresti A. Categorical Data Analysis [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2002
20. Yee TM. The VGAM package for categorical data analysis. J Stat Softw 2010;32:1-34
21. National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease [Internet]. 2011. Available at: http://www.nice.org.uk/guidance/ta217/resources/donepezil-galantamine-rivastigmine-and-mem antine-for-the-treatment-of-alzheimers-disease-82600254699973. Access date: 11/15/2015
22. Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015;138:1370-81
23. Boluda S, Toledo JB, Irwin DJ, et al. A comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathol 2014;128:543-50
24. Thal DR, Beach TG, Zanette M, et al. [(18) F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology. Alzheimers Dement 2015;11:975-85
25. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-8
26. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95
27. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-36
28. Schmitt FA, Davis DG, Wekstein DR, et al. "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology 2000;55:370-6
29. Delaère P, Duyckaerts C, He Y, et al. Subtypes and differential laminar distributions of beta A4 deposits in Alzheimer's disease: Relationship with the intellectual status of 26 cases. Acta Neuropathol 1991;81:328-35
30. Masliah E, Mallory M, Hansen L, et al. Quantitative synaptic alterations in the human neocortex during normal aging. Neurology 1993;43:192-7
31. Masliah E, Terry RD, Mallory M, et al. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am J Pathol 1990;137:1293-7
32. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989;135:309-19
33. Suenaga T, Hirano A, Llena JF, et al. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease. J Neuropathol Exp Neurol 1990;49:31-40
34. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, et al. Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:674-83
35. Grundke-Iqbal I, Fleming J, Tung YC, et al. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 1990;81:105-10
36. Itagaki S, McGeer PL, Akiyama H, et al. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989;24:173-82
37. Mattiace LA, Davies P, Dickson DW. Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol 1990;136:1101-14
38. Mattiace LA, Davies P, Yen SH, et al. Microglia in cerebellar plaques in Alzheimer's disease. Acta Neuropathol 1990;80:493-8
39. Ohgami T, Kitamoto T, Shin RW, et al. Increased senile plaques without microglia in Alzheimer's disease. Acta Neuropathol 1991;81:242-7
40. Sasaki A, Yamaguchi H, Ogawa A, et al. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol 1997;94:316-22
41. Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. J Neuropathol Exp Neurol 1996;55:273-9